Titan Pharmaceuticals issued the following announcement on June 4.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP)announced that it has executed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan's novel maintenance treatment for Opioid Use Disorder (OUD) in eligible patients.
"We are looking forward to working with Titan to provide patients with a unique, long-term maintenance treatment option for OUD," said Southside's Chief Executive Officer, Amit Jain. "California and Texasreported the nation's fourth- and sixth-highest number of opioid-related deaths, respectively, in 2017.1 With a large, established location in California, and numerous locations across Texas, we are proud to partner with Titan to positively impact OUD patients in our geographies."
"We are pleased to add Southside as one of Titan's valued specialty pharmacy partners, particularly given its strong presence in important markets in California and Texas," said Titan's Chief Commercial Officer, Dane Hallberg. "This partnership with Southside adds regional strength and reflects our ongoing effort to expand our network with additional well-established specialty pharmacies."
Titan expects the majority of Probuphine sales in the United States to be through the specialty pharmacy distribution model, where a specialty pharmacy carries inventory, directly handles the subsequent patients' insurance billing and payment processes, and ships to the healthcare provider as prescribed. This system is designed to facilitate patient access to treatment by streamlining the product ordering and fulfillment process for healthcare providers and their staff.
Titan announced specialty pharmacy agreements with AllianceRx Walgreens Prime in February 2019 and Accredo®specialty pharmacy, a subsidiary of Express Scripts, in May 2019.
Original source can be found here.